|
1.1 BIOLOGIE - GÉNOME
|
|
|
|
2.11 ETIOLOGIE - ALIMENTATION
|
|
|
|
3.1.1 PRÉVENTION - TABAC - E-CIGS
|
|
|
|
San Francisco Bans Sales Of E-Cigarettes [NPR]
|
|
|
|
|
|
"E-cigarettes are a product that, by law, are not allowed on the market without FDA review. For some reason, the FDA has so far refused to follow the law. If the federal government is not going to act, San Francisco will."
|
|
|
|
|
|
|
|
3.4 CHIMIOPRÉVENTION
|
|
|
Fish oil and cancer prevention [VUMC]
|
|
|
|
|
|
The findings, reported in the European Journal of Cancer Prevention, demonstrate a modest but beneficial effect of fish oil supplementation on molecules associated with colorectal cancer development and support further studies of fish oil fatty acids as cancer prevention agents.
|
|
|
|
|
|
|
4.1 DÉP., DIAG. & PRONO. - PROSTATE
|
|
|
|
Prostate cancer: New urine test hope [BBC News]
|
|
|
|
|
|
Georgina Hill, from Cancer Research UK, said the findings, published in BJU International, were "promising" but needed confirming in more patients before the test could be offered routinely.
|
|
|
|
|
|
|
4.10 DÉP., DIAG. & PRONO. - POUMON
|
|
|
Lung cancer screening: Women benefit significantly [DFKZ]
|
|
|
|
|
|
The lung cancer-specific mortality risk within the screening group was 26 percent lower, but the difference was not statistically significant. However, if the researchers separately calculated the lung cancer mortality rate of the female LUSI participants, there was a significant risk reduction of 69 percent in the screening group.
|
|
|
|
|
|
|
4.2 DÉP., DIAG. & PRONO. - GÉNOME
|
|
|
|
4.9 DÉP., DIAG. & PRONO. - SEIN
|
|
|
|
5.1 TRAITEMENTS - PRÉ-CLINIQUE
|
|
|
|
Tamp the Tumor [Harvard Medical School]
|
|
|
|
|
|
A growing body of evidence suggests that traditional cancer treatments can paradoxically promote new tumor growth. Now, a team of Harvard Medical School scientists has demonstrated that administration of anti-inflammatory treatments and proresolution treatments that tamp down the body’s inflammatory response can promote long-term survival in experimental animal models.
|
|
|
|
|
|
|
5.12 IMMUNOTHÉRAPIES
|
|
|
|
5.12.1 IMMUNOTHÉRAPIES - PARTENARIATS
|
|
|
|
|
5.12.2 IMMUNOTHÉRAPIES - CAR-T, THÉRAPIES CELLULAIRES
|
|
|
|
5.12.3 IMMUNOTHÉRAPIES-COMBINAISONS
|
|
|
|
5.2 PHARMA
|
|
|
GSK/Tesaro PARP inhibitor Zejula wins another speedy review [EndPoints]
|
|
|
|
|
|
The once-daily Zejula is currently being evaluated in three pivotal trials, including a late-stage trial in patients with first-line ovarian cancer (the PRIMA trial), a Phase III trial for the treatment of patients with germline BRCA-mutated, metastatic breast cancer (the BRAVO trial), and a registrational Phase II treatment trial in patients with ovarian cancer (the QUADRA trial).
|
|
|
|
|
|
|
5.2.2 PHARMA - FUSIONS & ACQUISITIONS
|
|
|
|
|
|
|
|
|
5.2.3 PHARMA - ÉCONOMIE
|
|
|
|
6.5 MÉDECINES ALTERNATIVES/COMPLÉMENTAIRES
|
|
|
|
6.6 PUBLICATIONS
|
|
|
|
6.7 DMP, BIG DATA & APPLIS
|
|
|
|
Jane Wilcock: The digitalisation of NHS patient care should be medically tested [BMJ]
|
|
|
|
|
|
No system is perfect. The only way for systems to improve is if we are transparent about failings and willing to correct them. This is a cornerstone of medical professionalism. In assessing novel technology we should compare efficacy and cost not to an underfunded, understaffed NHS with glitch-ridden systems, but to present systems if optimally funded and staffed.
|
|
|
|
|
|